SCHEMBL4465612

SCHEMBL4465612

Cc1ccc(Cl)cc1-c1ccc(CN2CCOCC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.59
USP2 O75604 2/20 0.54
TSHR P16473 2/20 0.54
PDE4B Q07343 2/20 0.52
CYP2A13 Q16696 1/20 0.51
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
TNKS O95271 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
MAPT P10636 2/20 0.48
HTT P42858 2/20 0.48
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.48
HPGD P15428 1/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
SLC2A1 P11166 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4469770 0.87 HRH3 (0.61) HRH3PDE4BCYP2A13TNKSSMN1; SMN2
SCHEMBL4473916 0.86 HRH3 (0.63) HRH3USP2TSHRPDE4BCYP2A13
SCHEMBL13161945 0.81 HRH3 (0.62) HRH3USP2TSHRCYP2A13KMT2A
SCHEMBL24495610 0.80 ALDH1A1 (0.60) HRH3SMN1; SMN2KDM4EALDH1A1HTT
SCHEMBL26371010 0.80 HRH3 (0.72) HRH3USP2TSHRCYP2A13TNKS
SCHEMBL4480082 0.78 KDM4E (0.56) HRH3CYP2A13SMN1; SMN2KDM4EALDH1A1
SCHEMBL4480084 0.78 KDM4E (0.56) HRH3CYP2A13SMN1; SMN2KDM4EALDH1A1
4-(4-Chlorobenzyl)Morpholine SCHEMBL4103722 0.78 HRH3 (0.74) HRH3USP2TSHRCYP2A13KMT2A
SCHEMBL14907097 0.78 CYP2A13 (0.67) USP2TSHRCYP2A13KMT2ANPSR1
SCHEMBL4476534 0.78 CNR2 (0.71)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
WO-2007070760-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor CNR1, CNR2, ARRB1 HRH3 283/4885USP2 3046/4885TSHR 386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.